Similarly, Yoneyama et al. measured serum α2–3-sialylated PSA using a magnetic microbead-based immunoassay in a training (n = 100) and a validation set (n = 314) of prostate cancer samples and suggested that α2–3-sialylated PSA may improve the accuracy of prostate cancer early detection [91]. This evidence concerns the gene KLK3 and prostate carcinoma.